Benjamin P. Levy, MD, discusses the evolution of liquid biopsies in all solid tumors, especially in non–small cell lung cancer (NSCLC) where they are used routinely.
Benjamin P. Levy, MD, an assistant professor of oncology and the clinical director of Medical Oncology at Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the evolution of liquid biopsies in all solid tumors, especially in nonsmall cell lung cancer (NSCLC) where they are used routinely.
Historically, Levy says liquid biopsies were initially used to detect resistance to EGFR targeted therapies, but more recently, 2 data sets demonstrated their utility in addition to tissue biopsies in patients with advanced NSCLC. In breast cancer and gastrointestinal (GI) malignancies, some utility for liquid biopsies has been demonstrated recently, but it has not been as ironed out as it has been in lung cancer.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More